1. People's Republic of China Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Qianjiang Yongan Pharmaceutical Co., Ltd.

Qianjiang Yongan Pharmaceutical Co., Ltd.

002365.SZ
Qianjiang Yongan Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
10.49
CNY
-0.44
- -
3.09BMarket Cap
Qianjiang Yongan Pharmaceutical Co., Ltd.
002365.SZ
(Shenzhen Stock Exchange)

Recent

price

10.49

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.2
1.47
1.67
1.82
2.35
1.89
1.94
3.2
3.45
4.74
4.07
5.28
4.96
3.3
2.86
2.71
2.7
Revenue per Share
0.17
0.25
0.27
0.08
0.11
0.06
0.22
0.46
0.61
0.31
0.37
0.38
0.48
-0.04
0.21
0.08
0.08
Basic EPS, GAAP
-0.23
-0.55
-0.17
-0.13
-0.11
0.12
0.16
-0.32
0.15
0.36
0.35
0.13
0.81
0.34
-0.04
0.27
-0.31
Free Cash Flow per Basic Share
0.16
0.11
0.13
0.14
0.02
0.04
0.02
0.06
0.07
0.1
0.16
0.1
0.01
0.12
0.1
0.1
0.07
Dividend per Share
1.07
1.46
1.57
1.48
1.59
1.53
1.76
2.08
2.9
3.11
3.3
3.45
3.9
3.76
3.86
3.89
3.86
Book Value per Share
3.62
3.48
3.62
3.47
3.67
3.53
3.88
4.29
5.18
5.39
5.95
6.28
6.82
6.67
6.69
6.58
6.67
Tangible Book Value per Share
266
283
283
288
281
294
283
292
291
289
288
296
295
295
293
289
289
Basic Weighted Avg Shares
320
417
471
523
658
556
549
933
1,005
1,370
1,173
1,565
1,462
973
839
783
780
Sales/Revenue/Turnover
12.38
16.43
16.32
3.27
4.3
0.23
7.51
19.31
18.75
8.5
11.77
8.3
11.03
1.15
4.57
-0.35
-0.4
Operating Margin (%)
13
16
19
40
56
70
71
70
80
113
113
116
124
135
113
117
- -
Depreciation Expense
46
70
75
23
32
18
62
133
179
90
106
111
140
-12
62
22
22
Net Income, GAAP
10.68
13.86
15
16.88
14.7
17.64
15.46
15.24
15.64
8.12
9.13
8.32
13.29
569.54
15.74
27.21
12.29
Effective Tax Rate (%)
14.42
16.73
16.01
4.4
4.82
3.17
11.34
14.27
17.76
6.56
9
7.12
9.6
-1.27
7.36
2.87
2.79
Profit Margin (%)
790
620
487
406
418
456
554
509
492
549
717
773
910
956
950
949
932
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1,015
1,056
1,094
1,080
1,108
1,119
1,177
1,345
1,606
1,657
1,814
1,957
2,103
2,048
2,042
1,982
2,006
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
16.74
18.93
16.41
5.71
7.06
2.66
11.54
23.76
24.05
8.06
9.01
9.36
12.33
0.17
5.36
3.29
2.27
Return on Capital (%)
16.74
20.01
17.61
5.3
7.28
3.93
13.13
24.08
24.62
10.32
11.41
11.29
12.92
-1.09
5.52
1.99
1.94
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
40
30
34
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
295
295
295
Market Capitalization
2,355
2,395
7,737

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,199
1,155
1,177
Cash, Cash Equivalents & STI
921
902
931
Accounts Receivable, Net
154
130
113
Inventories
94
90
101
Total Current Liabilities
248
218
244
Payables & Accruals
- -
- -
- -
ST Debt
40
30
34
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.1%
1.9%
-2.94%
Free Cash Flow
-74.13%
-88.11%
-722.87%
Net Income, GAAP
-37.32%
-148.5%
-63.58%
Sales/Revenue/Turnover
7.13%
-5.4%
-6.63%
Total Cash Common Dividend
233.57%
408.3%
0.22%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
197
229
193
220
839
2025
171
196
206
- -
783
2026
236
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
- -
- -
- -
0.21
2025
-0.02
- -
- -
- -
0.08
2026
0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.1
2025
- -
- -
- -
- -
0.1
2026
- -
- -
- -
- -
- -
Similar Companies
SRF Limited (SRF.NS)
Henan Qingshuiyuan Technology CO.,Ltd (300437.SZ)
NewGen Technologies Inc. (NWGN)
Hunan Lead Power Dazhi Technology Incorporated Company (300530.SZ)
Hubei Kailong Chemical Group Co., Ltd. (002783.SZ)
REC Silicon ASA (RNWEY)
Business
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of taurine and related pharmaceutical products. The company offers a comprehensive portfolio including medical taurine and food additive grade taurine, ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, creatine monohydrate, and various health products. Its taurine products serve multiple applications in medicines, food additives, feed, surface active agents, and whitening agents. The company operates primarily in China but also has a broad international market presence spanning Africa, Asia, Australia, Central and South America, Eastern Europe, the Middle East, North America, and Western Europe. Founded in 2001, Qianjiang Yongan Pharmaceutical is headquartered in Qianjiang, China. In the most recent major developments, the company completed a strategic acquisition in September 2025 by using 27 million yuan of its own capital to acquire the remaining 49.20% shares of its holding subsidiary Hubei Ling'an Technology Co., Ltd., thereby becoming the sole owner. This acquisition further consolidates its technological and production capabilities without altering the scope of its consolidated financial statement. Despite operational and market challenges reported in early 2025, including a temporary net loss in Q1 2025, the company continues to affirm stable production and business operations. The company has not engaged in direct online or cross-border e-commerce sales for taurine but utilizes a mixed sales model combining agent distribution and direct sales to end customers. The chairman faced investigation and detention in 2025 but has since been released, with ongoing normal company operations assured. Qianjiang Yongan Pharmaceutical holds multiple certifications including GMP, ISO9001, ISP22000, kosher, halal, FAMI-QS, and BRC, underscoring its compliance with international quality and safety standards. The company's extensive taurine production capacity of approximately 38,000 metric tons per year establishes it as a leading global taurine manufacturer. It participates actively in global trade exhibitions and promotes product innovation aimed at diverse industries such as pharmaceuticals, food, and animal feed additives. Overall, Qianjiang Yongan Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical company with a specialized focus on taurine and related chemical products, supported by recent strategic acquisitions and continued operational resilience since its founding in 2001 in Qianjiang, China.